Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
Can-Fite reported preclinical data showing namodenoson enhances the anti-cancer effect of gemcitabine in pancreatic cancer by increasing apoptosis. The findings provide mechanistic support for the design of the company's planned Phase IIb study combining namodenoson with gemcitabine and Nab-paclitaxel.
Key figures
- Patients studied
- 1600
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.